

A Study of Caldaserasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

NCT07219550

Status	RECRUITING
Phase	Phase 1
Sponsor	Merck Sharp & Dohme LLC
Enrollment	58 participants

Key Eligibility Criteria

Inclusion (6)

- All participants:
- Has a body mass index (BMI) between 18.0 and 42.0 kg/m²
- Participants with hepatic impairment (HI):
- Has a diagnosis of chronic, stable hepatic insufficiency at screening with features of cirrhosis
- Healthy volunteers:

... and 1 more (see full listing online)

Exclusion (20)

- All participants:
- Has a history of gastrointestinal disease which may affect food and drug absorption
- Has a history of cancer (malignancy)
- Has a positive result for human immunodeficiency virus (HIV)
- Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing

... and 15 more (see full listing online)

Locations (3 total)

Arizona Clinical Trials (Site 0003), Chandler, Arizona, United States
Orlando Clinical Research Center (Site 0001), Orlando, Florida, United States
The Texas Liver Institute (Site 0002), San Antonio, Texas, United States